The SETD7 (SET Domain Containing 7) antibody is a critical tool for studying the function and regulation of the SETD7 protein, a histone methyltransferase involved in epigenetic modifications. SETD7. also known as KMT7 or SET7/9. catalyzes the monomethylation of histone H3 at lysine 4 (H3K4me1), a post-translational modification associated with transcriptional activation. Beyond histones, SETD7 methylates non-histone targets, including transcription factors (e.g., p53. NF-κB) and signaling molecules (e.g., ERα, DNMT1), regulating their stability, localization, and activity. This dual role links SETD7 to diverse cellular processes, such as cell cycle control, differentiation, stress responses, and DNA repair.
Antibodies targeting SETD7 are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to detect protein expression, assess subcellular localization, and study interactions with substrates. Research has implicated SETD7 dysregulation in diseases, including cancer (tumor suppression or promotion depending on context), metabolic disorders, and neurodegenerative conditions like Alzheimer’s. For instance, SETD7-mediated p53 methylation enhances its tumor-suppressive activity, while aberrant SETD7 expression correlates with cancer progression.
Validating SETD7 antibody specificity is crucial, often achieved via knockout controls or siRNA knockdown. Commercial antibodies vary in performance across applications, requiring optimization for reliable results. Ongoing studies continue to unravel SETD7's complex roles, making its antibody indispensable for epigenetic and disease-related research.